A simple 3-day "rush" venom immunotherapy protocol: Documentation of safety

Allergologia et Immunopathologia

Volumn 38, Issue 2, 2010, Pages 69-73

  Kalogeromitros, D ^a   Makris, M ^a   Koti, I ^a   Chliva, C ^a   Mellios, A ^a   Avgerinou, G ^b   Theoharides, T C ^a,c  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Anaphylaxis; Hymenoptera; Immunotherapy; Safety; Venom

Indexed keywords

ADRENALIN; ALYOSTAL VENIN APIS MELLIFERA; ALYOSTAL VENIN POLISTES; ALYOSTAL VENIN VESPULA; ANTIHISTAMINIC AGENT; BEE VENOM; CORTICOSTEROID; IMMUNOGLOBULIN E; PHARMALGEN; UNCLASSIFIED DRUG; WASP VENOM;

ADOLESCENT; ADULT; AGED; ALLERGY; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; DOCUMENTATION; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYMENOPTERA; HYPERSENSITIVITY REACTION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; IN VIVO STUDY; INSECT ALLERGY; INSECT STING; MAINTENANCE DRUG DOSE; MALE; OUTPATIENT CARE;

ADULT; ANIMALS; ARTHROPOD VENOMS; CLINICAL PROTOCOLS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INSECT BITES AND STINGS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77951093245     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2009.08.002     Document Type: Article

References (27)

1. Bilo B.M., Bonifaci F. Epidemiology of insect venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008, 8:330-337.
2. Golden D.B. Insect sting anaphylaxis. Immunol Allergy Clin North Am 2007, 27:261-272.
3. Oude Elberink J.N., De Monchy J.G., Van Der H.S., Guyatt G.H., Dubois A.E. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002, 110:174-182.
4. Bonifazi F., Jutel M., Bilo B.M., Birnbaum J., Muller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005, 60:1459. the EAACI Interest Group on Insect Venom Hypersensitivity.
5. Müller U., Helbling A., Berchtold E. Immunotherapy with Honey Bee venom and Yellow Jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992, 89:529-535.
6. Mosbech H., Müller U. Side-effects of insect venom immunotherapy: Results from an EAACI multicenter study. Allergy 2000, 55:1005-1010.
7. Golden D., Valentine M.D., Kagey-Sobotka A., Lichtenstein L.M. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980, 92:620-624.
8. Lockey R.F., Turkeltaub P.C., Olive E.S., Hubbard J.M., Baird-Warren I.A., Bukantz S.C. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol 1990, 86:775-780.
9. Laurent J., Smiejan J.M., Bloch-Morot E., Herman D. Safety of Hymenoptera Venom Rush Immunotherapy. Allergy 1997, 52:94-96.
10. Sturm G., Kränke B., Rudolph C., Aberer W. Rush Hymenoptera venom immunotherapy: A safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002, 110:928-933.
11. Wenzel J., Meissner-Kraemer M., Bauer R., Bieber T., Gerdsen R. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 2003, 58:1176-1179.
12. Brehler R., Wolf H., Kütting B., Schnitker J., Luger T. Safety of a two-day ultra-rush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Immunol 2000, 105:1231-1235.
13. Birnbaum J., Ramadour M., Magnan A., Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210min): a safety study and risk factors. Clin Exp Allergy 2003, 33:58-64.
14. Roll A., Hofbauer G., Ballmer-Weber B.K., Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006, 16:79-85.
15. Pasaoglu G., Sin B.A., Misirligil Z. Rush hymenoptera venom immunotherapy is efficacious and safe. J Investig Allergol Clin Immunol 2006, 16:232-238.
16. Oren E., Chegini S., Hamilos D.L. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy. Ann Allergy Asthma Immunol 2006, 97:606-610.
17. Bilo B., Rueff F., Mosbech H. the EAACI Interest Group on Insect Venom Hypersensitivity, Diagnosis of Hymenoptera venom allergy. Allergy 2005, 60:1339-1349.
18. Ring J., Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977, 26;1:466-469.
19. Hoffman D.R., Jacobson R.S., Zerboni R. Allergens in hymenoptera venom XIX. Allergy to Vespa Crabro, the European Hornet 1987, 84:25-31.
20. Golden D. Insect sting Allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol 2005, 116:439-447.
21. Müller U. Recent developments and future strategies of immunotherapy of insect venom allergy. Curr Opin Allergy Clin Immunol 2003, 3:299-303.
22. Müller U., Hary Y., Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001, 107:81-86.
23. Moffitt J.E., Golden D.B., Reisman R.E., Lee R., Nicklas R., Freeman T., et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004, 114:869-886.
24. Kochuyt A.M., Stevens E.A.M. Safety and efficacy of a 12-week maintenance interval in patients treated with Hymenoptera venom immunotherapy. Clin Exp Allergy 1994, 24:35-41.
25. Goldberg A., Confino-Cohen R., Mekori Y.A. Deliberate bee sting challenge of patients receiving maintenance venom immunotherapy at 3-month intervals. J Allergy Clin Immunol 1994, 93:997-1001.
26. Glerant J., Martinez P., Guillaume C., Jounieaux V. Comparison of 2 maintenances doses (100microg vs 200microg) in Hymenoptera venom immunotherapy: influence of the maintenance dose on the immunologic response. Ann Allergy Asthma Immunol 2005, 94:451-456.
27. Forester J.P., Johnson T.L., Arora R., Quinn J.M. Systemic reactions rates to field stings among imported fire ant-sensitive patients receiving >3 years of immunotherapy versus <3 years of immunotherapy. Allergy Asthma Proc 2007, 28:485-488.